Sam Altman has no shortage of ambition. And now, he’s coming after extending the life expectancy of humans.
What’s happening:
- Longevity startup Retro Biosciences has officially announced they will raise $1B USD in a new Series A financing round
Why it matters:
- OpenAI co-founder Sam Altman is one of the largest investors in Retro Biosciences, previously investing $180M USD into the company
Going deeper:
- Retro Bioscience just recently announced they have built a new artificial intelligence model in partnership with OpenAI that is aiming to make new breakthroughs around longevity science and extending human lifespan
- The new capital raise is aiming to accelerate three new drugs from Retro Biosciences into advanced clinical trials, including new drugs for blood cell rejuvenation and Alzheimers
